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Background: Recent studies show that COPDpatients exhibit low-grade systemic inflammation, and
that plasma fibrinogen and high neutrophil counts are related to faster declines in lung function.We
examined correlations between serumbiomarkers and thedecline of lung function inCOPDpatients.
Method: Baseline levels of 9 serum biomarkers (TIMP-1, a1-antitrypsin, MMP-9, TNF-a, TGF-b, IL-6,
IL-8, neutrophil elastaseandCRP),fibrinogenandwhitebloodcell counts (WCC)weremeasured in96
COPD patients. Lung function was measured at the time of blood sampling and every 3e6 months
during the observation period (median 25.0 months).
Results: Twenty patients were rapid decliners of lung function and 53 patients were non-decliners.
Neutrophil counts, serum CRP and MMP-9 were significantly higher in the rapid decliners (p< 0.05).
The annual change of % predicted FEV1 was inversely correlated with MMP-9 (rZ0.288; p< 0.01)
and CRP (rZ0.354; p< 0.005) (partial correlation coefficients adjusted for age, sex, cardiovas-
cular disease, smoking history, and baseline % predicted FEV1). The remaining biomarkers were
not correlated with the annual change of % predicted FEV1.
Conclusion: Serum CRP and MMP-9 levels were related to FEV1 decline. These markers are good
candidates as predictors for rapid decline of FEV1 in COPD patients. Additional long-term and larger
size studies of COPD patients could help determine the exact roles for these biomarkers.
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. Tel.: þ81 72 366 0221; fax: þ81 72 366 0206.
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Table 1 Characteristics of 96 patients with COPD.
Characteristicsa Median N IQR
Observation period (months) 25.0 13.0e37.8
Age (years) 79 82.0e72.3
Males 95
Smoking status
Current smoker 24
Non-current smoker 72
Never smoked 0
Smoking history (pack-years) 50.0 37.0e75.0
BMI 21.2 19.0e23.0
FEV1/FVC ratio 58.4 50.8e65.1
FEV1 (L) 1.5 1.0e2.0
FEV1/% predicted 69.6 49.6e87.7
FVC (L) 2.5 2.0e3.1
COPD
stage I 37
stage II 35
stage III 21
stage IV 3
Long-term oxygen therapy 20
IQR: interquartile range.
a Measured at recruitment.
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Chronic obstructive pulmonary disease (COPD) is a slowly
progressive disease induced primarily by smoking tobacco.
FEV1 is easily measured and is a spirometric predictor of
mortality in patients with COPD.1 Factors that affect the
decline of FEV1 are, therefore, of prognostic importance in
COPD. Long-term studies of the natural history of COPD
have shown the importance of tobacco smoking and exac-
erbation frequency.2,3 Some smokers are more predisposed
to rapid declines in lung function (‘‘rapid decliners’’) than
others (‘‘slow decliners’’).3e5 However, there is little
information available regarding what factors contribute to
the differences for these two types of patients.
Recent studies have shown that patients with COPD
exhibit low-grade systemic inflammation6,7 that is often
associated with significant extra-pulmonary effects, such as
cardiovascular abnormalities and skeletal muscle dysfunc-
tion.6 Gan et al. performed a systematic review of these
studies and found that circulating leukocytes, fibrinogen,
serum c-reactive protein (CRP) and tumor necrosis factor-
a (TNF-a) levels were higher in COPD patients than in control
subjects.8Wepreviously reported that serumconcentrations
of tissue inhibitor of metalloproteinase-1 (TIMP-1), a1-anti-
trypsin (a1-AT), TNF-a, and IL-6 levelswere elevated inCOPD
patients.9,10 Circulating CRP levels have been reported as
a predictor of mortality in COPD.11,12 However, there is little
information on how these inflammatory markers are related
to lung function decline in COPD. Donaldson et al. reported
that patients with high plasma fibrinogen levels and
neutrophil counts had a faster % predicted FEV1 decline.
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The aim of this study was to examine which inflamma-
tory markers were related to a faster decline of FEV1 in
COPD patients, and also to examine the effect of smoking
status and steroid treatment.
Methods
Subjects
COPD was defined according to the GOLD criteria.14 COPD
was diagnosed when the post-bronchodilator FEV1/FVC
(forced vital capacity) ratio was less than 70% (GOLD stages
IeIV). A total of 96 patients with COPD were recruited from
patients seen in the Department of Internal Medicine of the
Wakayama Medical University Kihoku Hospital. Character-
istics of the 96 COPD patients are shown in Table 1. All
subjects were in a clinically stable condition, were not
suffering from respiratory tract infections and did not
experience disease exacerbation at least 4 weeks prior to
blood sampling. Eleven patients were diabetic, 10 patients
had cardiovascular disease, 4 patients had hyperlipidemia,
5 patients had chronic liver disease, 3 patients had gall
bladder stones, and 8 patients had chronic gastritis.
However, patients were excluded if they had bronchiec-
tasis, tuberculosis or other confounding inflammatory
diseases, such as malignancy, arthritis, connective tissue
disorders or inflammatory bowel disease. The study was
approved by the Ethics Committee of the Wakayama
Medical University, and all patients gave informed consent
for participation.Measurements of hs-CRP, a1-antitrypsin, IL-8, IL-6,
TNF-a, neutrophil elastase, TGF-b1, MMP-9 and
TIMP-1
Serum high-sensitivity (hs) CRP was measured by immune
nephelometry using the TBA-200FR NEO system (Toshiba
Medical Systems; Tokyo, Japan),with a lower detection limit of
<0.030 mg/dl. Serum a1-antitrypsin (a1-AT) was also deter-
mined using immune nephelometry.10,15 Tumor necrosis factor
(TNF)-a, interleukin (IL)-8, IL-6, TGF-b1, neutrophil elastase,
Matrix metalloproteinase (MMP)-9 and TIMP-1 concentrations
weremeasuredbyenzyme-linked immunosorbentassay (ELISA)
kits (Amersham Biosciences AB, Uppsala, Sweden; BioLegend,
San Diego, CA; Alexis, Lausen, Switzerland). All assays were
performedaccording to themanufacturers’ recommendations.
Categorization of smoking status
Subjects were categorized as current smokers, non-current
smokers (former smokers) and those who had never
smoked. To confirm smoking status, we measured serum
cotinine levels using an enzyme-immunoassay (EIA) serum
cotinine kit (Cozart Bioscience, Oxfordshire, UK). Cotinine
is the main metabolite of nicotine. As significant serum
concentrations of cotinine reflect exposure to tobacco
smoke during the previous few days, measurement of serum
cotinine allowed the objective classification of non-current
and current smokers. A cotinine concentration >25 ngmL1
was considered positive for smoking.10,16Pulmonary function tests
Pulmonary function tests (Chestac-8800, Chest Ltd, Tokyo,
Japan) were performed within 1 month prior to blood
Table 2 Adjusted correlation coefficients for annual
changes of % predicted FEV1 with biomarkers and emphy-
sema scores in COPD patients.
Parameters N Adjusted correlation
coefficient (r)
p-Value
BMI (kg/m2) 96 0.099 0.357
WCC (109 L1) 76 0.207 0.087
Neutrophil counts
(109 L1)
28 0.394 0.057
Fibrinogen (mg L1) 52 0.286 0.054
MMP-9 (ng mL1) 90 0.288 0.008a
TNF-a (pg mL1) 75 0.142 0.245
IL-6 (pg mL1) 84 0.015 0.897
TGF-b (ng mL1) 89 0.214 0.054
TIMP-1(ng mL1) 88 0.005 0.961
Elastase (ng mL1) 56 0.160 0.266
a1-AT (mg L1) 87 0.138 0.221
IL-8 (pg mL1) 90 0.022 0.845
hs-CRP (mg L1) 84 0.354 0.002a
Goddard score 47 0.143 0.373
Adjusted for age, sex, cardiovascular disease, smoking history
(pack-years), and baseline FEV1 % predicted.
WCC: white blood cell count, BMI: body mass index.
a Significant correlation with annual change of % predicted
FEV1.
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during the observation period (median 25.0 months; inter-
quartile range [IQR] 13.0e37.8 months). Lung function was
assessed as % predicted FEV1, with FEV1 adjusted for age,
height and sex. Rapid decliners had a decrease in % pre-
dicted FEV1 3.0%/year and non-decliners had an increase
in % predicted FEV1 0.4%/year.4,5
Visual emphysema score
Pulmonary emphysema was assessed visually by 3 expert
chest radiologists who were blinded to the clinical and lung
function data, as described by Goddard et al.17 Based on 3
high-resolution computed tomography (HRCT) slices (at the
level of the carina, and at 5 cm above and below the
carina), lung parenchyma were assessed for the extent of
emphysema. The 3 HRCT slices were graded and scored
separately for the left and right lungs, giving a total of 6
lung fields. The extent of emphysema using this direct
observation method was scored on a 4-point scale. The
extent score was 1 if <25% of the lung field was involved, 2
if there was 25e50% involvement, 3 for 50e75% involve-
ment, and 4 for >75% involvement. The sum of the extent
scores for the 6 lung fields had a possible maximum value of
24. The average score given by the 3 radiologists was used.
Statistical analysis
Patients’ characteristics recorded at recruitment are given
as medians (interquartile range [IQR]) (Table 1). Results are
shown as the mean standard error of the mean (SEM).
Comparisons between groups were done using unpaired
Student’s t-tests. Comparisons between COPD stages were
made using analysis of variance (ANOVA), followed by
Fisher’s protected least-significant difference (PLSD) test.
Correlation analysis used partial correlation coefficients
adjusted for age, sex, cardiovascular disease, smoking
history (pack-years) and baseline FEV1 % predicted. Step-
wise multiple regression analysis was done for any inde-
pendent variable that showed significant predictor value in
the univariate analysis; a p-value >0.25 was used for vari-
able removal. A p-value <0.05 was considered statistically
significant.
Results
Patient characteristics
The 96 patients (95 men) studied had mild to very severe
COPD (Table 1). Of these, 20 patients were receiving home
oxygen therapy, 10 were receiving inhaled steroids daily, 5
were receiving oral steroids and one patient received both
kinds of steroids. Four patients died during the follow-up
period. Three patients were receiving non-invasive positive
pressure ventilation (NIPPV).
Annual changes of lung function
On average, the annual changes of FEV1 and the FEV1/FVC
ratio declined by 20.2 mL/year and 0.41%/year,respectively. The average annual changes for % predicted
FEV1 and FVC increased by 0.94%/year and 8.8 mL/year.
Twenty patients were rapid decliners of lung function,
whose decline of % predicted FEV1 was >3%/year
(DFEV1Z179 29.4 mL/year), and 53 were non-
decliners (DFEV1Zþ58.8 11.4 mL/year).
Correlations between annual changes of lung
function and biomarkers
The annual changes of % predicted FEV1 were significantly
correlated with serum MMP-9 (rZ0.288; p< 0.01) and
CRP (rZ0.354; p< 0.005) (partial correlation coeffi-
cients adjusted for age, sex, cardiovascular disease,
smoking history and baseline % predicted FEV1) (Table 2).
These markers were also inversely correlated with the
annual changes of FEV1 values (MMP-9: rZ0.277,
p< 0.05; CRP: rZ0.303, p< 0.01). These biomarkers
were not correlated with the annual changes of other lung
function parameters, including FVC, VC and % predicted VC.
The remaining biomarkers were not significantly correlated
with the annual changes for FEV1, % predicted FEV1 or FVC.
Stepwise multiple regression analysis was done for any
independent variable that showed significant predictor
value from the univariate analyses (MMP-9 and CRP). MMP-9
and CRP were independent predictors of the annual
changes of % predicted FEV1 (R
2 for the overall model was
0.14, p< 0.005). Thus, only a small proportion of the vari-
ance (14%) for the annual change of % predicted FEV1 was
explained by CRP and MMP-9 concentrations.
Neutrophil counts and serum MMP-9 and CRP levels were
significantly higher in rapid decliners of FEV1 compared to
non-decliners (Table 3). The remaining biomarkers and BMI
were not significantly different between the 2 groups.
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(Goddard scores) and annual changes of FEV1
Baseline lung function parameters (FEV1, % predicted
FEV1and FVC) were not correlated with the annual changes
of % predicted FEV1 (rZ0.060, pZ 0.574; rZ0.104,
pZ 0.328; rZ0.047, pZ 0.663, respectively) (partial
correlation coefficients adjusted for age, sex, cardiovas-
cular disease, smoking history), and were not significantly
different between rapid decliners and non-rapid decliners
(data not shown). The annual FEV1 decline tended to be
greater in mild disease than severe disease, although the
differences were not significant (GOLD stage I:
26.1 27.9 mL/year; stage II: 25.2 21.9 mL/year;
stage III: 10.8 17.3 mL/year; stage IV: 47.5 21.4 mL/
year). The annual changes of % predicted FEV1 were not
different by GOLD stages.
Emphysema was evaluated by HRCT in 47 patients.
Goddard scores at the start of the study period were not
correlated with the annual changes of % predicted FEV1
(Table 2). Goddard scores were not different between rapid
decliners and non-decliners (Table 3). Serum a1-AT levels
were significantly correlated with Goddard scores
(rZ 0.3926, pZ 0.0084).
Influence of smoking status on biomarkers and lung
function changes
Serum levels of TNF-a (pZ 0.010) and IL-8 (pZ 0.025)
were significantly higher in current smokers compared to
non-current smokers (Table 4). The other biomarkers were
not affected by smoking status. Annual changes of lung
function parameters (FEV1, % predicted FEV1 or FVC) were
not different between current smokers and non-current
smokers. There was no correlation between smoking history
(pack-years) and the annual changes of FEV1 or % predicted
FEV1 (Table 2), although the extent of FEV1 decline for
current smokers tended to be greater than that of non-Table 3 Biomarkers and emphysema scores: Comparisons betw
Parameters Non-decliners
Mean SE n
Age (years) 77.6 1.1 53
BMI (kg/m2) 21.2 0.4 53
WCC (109 L1) 6.44 0.30 40
Neutrophil counts (109 L1) 3.31 0.24 15
Fibrinogen (mg L1) 304 12 27
MMP-9 (ngmL1) 197 19 48
TNF-a (pg mL1) 7.44 0.34 41
IL-6 (pg mL1) 4.66 1.06 46
TGF-b (ng mL1) 50.5 2.5 47
TIMP-1(ng mL1) 201 6 46
Elastase (ng mL1) 106 13 27
a1-AT (mg L1) 146 5 46
IL-8 (pg mL1) 13.3 1.5 48
hs-CRP (mg L1) 0.21 0.04 43
Goddard score 8.62 1.27 21
Non-decliner: increase in % predicted FEV1 0.4%/year, Rapid declin
a Significant difference by unpaired t-test.current smokers (Table 4). Smoking history (pack-years)
was not different between rapid decliners and non-
decliners (71 18 and 57 5, pZ 0.195).
Effect of inhaled or oral steroid treatment on
biomarkers and annual changes of lung function
Inhaled or oral steroid treatment had no significant effect
on lung function changes. Annual changes of FEV1 or %
predicted FEV1 were not different between the patients
with and without steroid treatments (Table 5). WCC and IL-
8 serum levels were significantly higher in the patients
receiving steroids compared to those without steroid
treatment. The levels of other biomarkers were not
significantly different between the COPD patients with and
without steroid treatment.
Discussion
Serum CRP and MMP-9 levels and circulating neutrophil
counts were related to an accelerated rate of FEV1 decline
in COPD patients. However, the available data are limited
regarding blood biomarkers as predictors of lung function
decline in COPD. Donaldson et al. reported that high plasma
fibrinogen levels and circulating neutrophil counts were
associated with a faster % FEV1 decline in COPD.
13 This is
consistent with our results that neutrophil counts were
higher in rapid decliners compared to non-decliners. They
also showed that frequent exacerbators have faster rises in
airway and systemic inflammatory markers. Frequent
exacerbators, with an exacerbation frequency of >2.52
exacerbations per year, were more likely to show a faster
rise in plasma fibrinogen and sputum IL-6 over time than
patients with a history of infrequent exacerbations.13
These results suggest that increased airway inflamma-
tion, due possibly to frequent exacerbations, is associated
with a faster lung function decline in patients with COPD.
However, the primary cause for systemic inflammation ineen COPD rapid decliners and non-decliners of lung function.
Rapid decliners p-Value
Mean SE n
78.6 2.0 20 0.655
21.5 0.9 20 0.751
7.31 0.59 18 0.156
4.80 0.82 6 0.030a
345 19 14 0.069
285 49 20 0.046a
7.32 0.56 16 0.861
5.11 1.42 18 0.812
57.6 3.4 20 0.109
208 9 20 0.520
132 26 14 0.315
144 5 18 0.858
13.5 1.7 20 0.925
0.56 0.23 20 0.042a
8.54 1.95 13 0.971
er: decrease in % predicted FEV1 3%/year.
Table 4 Influence of smoking status on annual changes of lung function, biomarkers and emphysema scores.
Parameters Non-current smokers Current smokers p-Value
Mean SE n Mean SE n
FEV1 annual change (mL/year) 15.5 16.6 58 41.1 27.9 32 0.402
% predicted
FEV1 annual change (%/year) 1.00 0.96 57 0.20 1.34 31 0.626
BMI (kg/m2) 21.2 0.4 58 20.4 0.8 31 0.321
WCC (109 L1) 6.49 0.27 51 6.73 0.50 25 0.643
Neutrophil counts (109 L1) 3.60 0.33 20 3.89 0.70 8 0.674
Fibrinogen (mg L1) 321 13 32 361 30 16 0.149
MMP-9 (ng mL1) 219 21 58 202 32 32 0.635
TNF-a (pg mL1) 6.91 0.32 53 8.35 0.31 22 0.010a
IL-6 (pg mL1) 4.10 0.54 56 5.97 1.72 28 0.193
TGF-b (ng mL1) 53.9 1.9 58 51.8 3.6 31 0.551
TIMP-1 (ngmL1) 193 6 58 213 8 30 0.056
Elastase (ng mL1) 117 12 42 117 23 14 0.980
a1-AT (mg L1) 142 4 55 143 4 27 0.778
IL-8 (pg mL1) 11.5 0.7 58 15.7 2.1 32 0.025a
hs-CRP (mg L1) 0.24 0.07 54 0.36 0.10 30 0.370
Goddard score 9.27 1.03 37 8.20 2.36 10 0.648
a significant difference by unpaired t-test.
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et al. examined the relationship between airway inflam-
mation and systemic inflammation. There was no relation-
ship between sputum IL-6 and plasma fibrinogen, suggesting
that there is no direct link between systemic and airway
inflammation. Another study also showed that these two
compartments were not related. Vernooy reported that
there were no direct correlations between sputum and
plasma sTNF receptors in patients with COPD.18
These results suggest that systemic inflammation in
COPD is not due to an overflow of inflammatory mediators
from the local compartment. Rather, this implies that the
inflammatory responses in the local and systemic
compartments are regulated differently. Systemic hypoxia
has been suggested to be a good candidate, as systemicTable 5 Influence of inhaled or oral steroids on annual change
Parameters Without steroids
Mean SE
FEV1 annual change (mL/year) 25.2 15.7
% predicted
FEV1 annual change (%/year) 0.84 0.85
WCC (109 L1) 6.23 0.23
Fibrinogen (mg L1) 322 14
MMP-9 (ng mL1) 203 18
TNF-a (pg mL1) 7.17 0.29
IL-6 (pg mL1) 4.58 0.76
TGF-b (ng mL1) 51.9 1.9
TIMP-1 (ngmL1) 199 6
Elastase (ng mL1) 114 11
a1-AT (mg L1) 143 3
IL-8 (pg mL1) 12.3 0.6
hs-CRP (mg L1) 0.245 0.06
a Significant difference by unpaired t-test.hypoxia is associated with activation of the TNF-a system in
patients with COPD. In line with this hypothesis, Takaba-
take and colleagues recently reported that systemic
hypoxia observed in patients with COPD, due to deteriora-
tion of lung function, might contribute to enhanced levels
of systemic inflammatory markers.19 However, systemic
hypoxia will usually occur only in very severe disease.
Additional studies are clearly required to elucidate the
origin and regulation of the systemic inflammatory response
in COPD.
MMP-9 has been implicated in human emphysema, with
its principal effect being the destruction of the extracel-
lular matrix, particularly elastin.20 The protease:anti-
protease hypothesis has dominated thinking regarding the
pathogenesis of emphysema. Studies of human sampless of FEV1, % predicted FEV1 and biomarkers.
With steroids p-Value
n Mean SE n
82 9.0 23.9 14 0.389
82 1.55 1.15 14 0.735
64 8.39 0.73 12 0.001a
44 366 23 8 0.212
76 269 51 14 0.171
62 8.15 0.57 13 0.149
71 5.50 1.44 13 0.626
75 60.2 3.5 14 0.081
74 207 9 14 0.542
48 136 30 8 0.462
74 145 7 13 0.738
76 17.1 4.6 14 0.047a
71 0.475 0.244 13 0.184
1236 Y. Higashimoto et al.show increases in many proteases, including MMP-1, -2, -8,
-9, and -14 (MT1-MMP) in smoking-related emphysema.21
Lung parenchyma destruction by elevated MMP-9 may
contribute to additional airflow limitations (FEV1 decline)
by decreasing lung elastic recoil. In the normal lung, MMP-9
is not produced by resident cells. However, under various
forms of stimulation, numerous cell types in the lung will
produce MMP-9. These include bronchial epithelial cells,
Clara cells, alveolar type II cells, fibroblasts, smooth muscle
cells, endothelial cells, leukocyte, lymphocytes, eosino-
phils, mast cells, NK cells, dendritic cells and macrophages.
Thus, many types of lung cells may contribute to MMP-9
production under pathological conditions. Pinto-Plata et al.
compared the serum proteomic profiles for 143 serum
biomarkers in patients with COPD with those from age and
sex-matched controls using a novel protein microarray
platform (PMP) technology.22 By univariate analyses, 43
biomarkers, including TIMP-1 and MMP-9, were identified
that differed between patients and controls. Among these
markers, serum MMP-9 showed the strongest correlation
with exacerbation rates. They suggested that MMP-9 may
be related to the rapid decline of FEV1 with regard to the
rate of exacerbation. Our results support this hypothesis.
However, the source(s) of circulating MMP-9 for COPD
patients remains to be elucidated.
CRP is the most well-studied biomarker of systemic
inflammation in COPD.12 CRP levels in stable COPD are
elevated, and are correlated with arterial oxygen tension
and 6-min walk distance.11 However, the predictive value
of CRP for COPD prognosis is still controversial. Gan and co-
workers were the first to note the importance of high CRP
levels in COPD patients. They showed that CRP is elevated
in patients who are active smokers, had reduced lung
function or had stable COPD. They also demonstrated that
for patients with COPD, CRP levels predicted cardiovascular
mortality, and decreased after treatment with inhaled
corticosteroid.8,23
A role for CRP levels as a predictor of cardiovascular and
global mortality in the general population has been postu-
lated, but has not yet been fully accepted.24 Two epide-
miologic studies showed that increased CRP levels were
independently associated with global and cardiovascular
mortality in COPD patients with mild-to-moderate degrees
of airway obstruction.12,25 In the first study for individuals
from the Lung Health Study with mild-to-moderate airway
obstruction,25 Man et al. found that patients in the highest
CRP quartile had the highest risk of all-cause mortality.
Recently, Dahl et al., using data from the Copenhagen City
Heart Epidemiologic Study, found that the CRP level was
a strong, independent predictor of COPD outcomes repre-
sented by hospitalization and death.12 However de Torres
et al. reported that CRP levels were not associated with
mortality in moderate-to-severe COPD patients.26 They
speculated that this discrepancy was due to the differences
of severity for the subjects in these studies.
The 2 former studies used mild-to-moderate COPD with
few or no symptoms in contrast to the latter report that
studied moderate-to-severe disease. CRP is an acute-phase
reactant that increases in a very sensitive, but non-specific
way for most forms of tissue damage, inflammation and
infection, all of which are very dynamic processes in
patients with COPD. Further, CRP levels can be influencedby many different factors, including cardiovascular
disease,27 degree of physical activity, diabetes,28 renal
disease, hypertension, metabolic syndrome, obstructive
sleep apnea, smoking status and treatments, such as sta-
tins. These confounding factors may influence the results
when we discuss the value of CRP as a predictor for prog-
nosis in COPD. In our study, 11 patients were diabetic and
10 patients had cardiovascular disease. These conditions
may have influenced the results.
Emphysema scores and lung function parameters at the
beginning of the study were not related to the annual
changes of FEV1. However, patients with mild-to-moderate
disease tended to have faster declines compared to the
patients with severe to very severe disease, although the
differences were not significant. This is consistent with
a previous study that found that patients with a high
starting value for % predicted FEV1 had a faster decline.
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This is contrary to the conventionally accepted idea that
a high initial FEV1 is related to a slow decline, and that
a low initial FEV1 is related to a fast decline. Fletcher
et al.29 cautioned against this assumption in their landmark
monograph. A slower decline in a group of patients with
very severe COPD may be due, in part, to a survival effect,
with faster decliners absent due to death or the use of
intensive therapy in the latter stages of the disease.
Smoking status was not related to the annual changes of
FEV1 in this study, although the annual FEV1 decline for
current smokers tended to be greater than that of non-
current smokers. It has been suggested that there is
a doseeresponse relationship between the number of pack-
years smoked and lung function decline.30 Subjects who
continued to smoke experienced steeper rates of decline
compared with men who never smoked. After quitting,
their rates of decline diminished to a level similar to that of
men who had never smoked. FEV1 decline in continuing
smokers was significantly associated with duration of
smoking, intensity and pack-years. The Lung Health Study
(LHS) also showed that smoking cessation early in the
course of COPD can slow the rate at which lung function is
lost.31 After 5 years, smoking cessation significantly
reduced the rate of decline in lung function, although the
use of a bronchodilator did not influence the long-term
decline of FEV1.
In our study, serum levels of TNF-a and IL-8 were higher
in current smokers than in non-current smokers. Previous
studies showed that active cigarette smoking, which is
a leading risk factor for decreased FEV1, can also inde-
pendently induce systemic inflammation. Gan et al.
examined the effects of active smoking and lung function
decline on the elevation of systemic inflammatory markers
(CRP, fibrinogen, and leukocyte) using 7685 adult partici-
pants in the Third National Health and Nutrition Examina-
tion Survey.23 They found an additive effect of active
smoking and reduced FEV1 for these markers, suggesting
their potential interactions in the pathogenesis of systemic
complications observed in patients with poor lung function.
The annual changes of FEV1 were not different by use of
inhaled corticosteroid (ICS) or oral steroid in this study. The
effectiveness of ICS in patients with COPD remains
controversial. Randomized controlled trials, meta-anal-
yses, medication withdrawal studies and observational
reports have examined this question, with mixed results.
Serum biomarkers and lung function decline in COPD 1237Two meta-analyses of the results from 4 large studies
together with several other smaller trials reported contra-
dictory conclusions.32,33
One group concluded that ICS reduced FEV1 decline by
a small, but statistically significant mean rate of 7.7 mL/
year, whereas a second group concluded that the reduction
in the mean rate was only 5.0 mL/year and was not statis-
tically significant. Sin et al. reported that 2 weeks use of
inhaled fluticasone or oral prednisone significantly reduced
CRP levels from baseline levels in 41 mild-to-moderate
COPD patients, and suggested the potential use of these
drugs for improving cardiovascular outcomes in COPD.34
However, they recently reported that neither fluticasone
nor the combination of fluticasone/salmeterol (4 weeks)
had a significant effect on CRP or IL-6 levels in a larger
double-blind randomized placebo-controlled multicenter
trials (289 patents).35 They speculated that the discrepancy
between the studies arose from the difference of subjects’
backgrounds, including disease severity, smoking status and
former ICS use.
In the same study, they showed that fluticasone reduced
circulating SP-D levels compared to placebo, and that,
conversely, withdrawal of the drug increased SP-D levels.
They suggested that ICS reduced lung-specific, but not
generalized biomarkers of systemic inflammation in COPD,
such as CRP. In our study, CRP and IL-6 levels were not
different by use of ICS. However, peripheral white blood
cell counts and IL-8 serum levels were greater in COPD
patients receiving steroid treatments than in those without
steroids. Glucocorticoids are known to cause a marked
increase in circulating polymorphonuclear (PMN) cells.36
Thus, steroid treatment may increase PMN in COPD. Back-
ground disease status may influence circulating PMN rather
than the steroid treatment, because we used steroids
mostly for severe disease or for those patients with asth-
matic components.
This study was limited by its observational nature,
the short observation period and the relatively small
number of subjects, especially for discussion of the
absolute outcomes of COPD (mortality). We measured
biomarkers at a single point only. As suggested by
Donaldson, longitudinal studies are needed to confirm
the reliability of these markers and their relationships
to other clinical factors.13 Our data set is incomplete.
Inflammatory markers and visual emphysema scores
(HRCT) were not available for all patients. This may
have caused a type II error in the statistical analysis.
Multiple backward stepwise regressions showed that
MMP-9 and CRP were independent predictors of annual
changes of FEV1. However, only a small proportion of
the total variance (14%) for annual changes of FEV1 was
explained by these markers. Additional large scale
studies with longer observation periods will be
required.
In summary, we have shown for the first time that high
levels of circulating MMP-9 and CRP, as well as neutrophil
counts, are associated with rapid decline of FEV1 in
COPD. These results suggest that these circulating
biomarkers are good candidates as predictors for rapid
decline of FEV1 in COPD, although a larger size study with
longer term observation is needed to confirm these
results.Conflict of interest
The authors declare that none of them has any conflict of
interest related to the article or the research described.
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